Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was more active in the last trading session as around 1.9 million shares exchanged hands on Wall Street, representing an increase from its normal capacity of 1.31 million shares. A -4.3% change after the initial price of $15.17, sent the closing price to $15.12.Ironwood Pharmaceuticals, Inc. (IRWD) Analyst Opinion
Ironwood Pharmaceuticals, Inc. has a consensus outperform rating from 12 Wall Street analysts, and the number of shares currently sold short amount to at least 13.18% of shares outstanding. The stock sank -0.72% last month and is down -1.11 this year. Wall Street is only getting more bullish on the stock, with 6 of analysts who cover IRWD having a buy-equivalent rating. Analysts have placed a $17.08 price target on Ironwood Pharmaceuticals, Inc., suggesting a 12.96% gain from recent close. It’s currently trading about -24.17% below its 52-week high.
Ironwood Pharmaceuticals, Inc. (IRWD) surprised the stock market in its last reported earnings when it earned -$0.18 a piece versus the consensus-estimated -$0.22. Its revenue totaled $73.6 million up 13.09% from the previous quarter.Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Intraday View
This stock (IRWD) is ahead of its 52-week low with 12.58%. Its last month’s stock price volatility remained 4.66% which for the week stands at 3.13%. The share price has moved backward from its 20 days moving average, trading at a distance of -4.1% and stays -3.54% away from its 50 days moving average. Over the last five days, shares have faced -11.73% losses and now is down -9.26% since hitting its 200-day moving average of $16.56. Ironwood Pharmaceuticals, Inc. (IRWD) has made its way to a 12-month decline of -1.75%.
Turning to Nektar Therapeutics (NASDAQ:NKTR), its shares were trading at $49.69 a retreat of $-2.23, on the trading floor. The stock, after opening at $51.86, touched a high of $52.35 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.6. Nektar Therapeutics has 5 buy ratings, 1 holds and 0 sells even after the stock tumbled -10.34% from its high of $55.42 to a $7.85 billion market value through last close.
The company’s consensus rating on Reuter’s scale slipped from 1.7 to 1.64 during a month. Analysts set a 12-month price target of $36.5 a share. The target implies a -26.54% decrease from where the shares are currently trading. Also, the current price highlights a discount of 0.62% to analysts’ high consensus price target.Nektar Therapeutics (NASDAQ:NKTR) Intraday Trading
The counter witnessed a trading volume of 2.85 million shares versus an average volume of 2.08 million shares during last trading session. Its last month’s stock price volatility remained 6.54% which for the week approaches 7.86%. The lowest price the stock reached in the last trading day was $48.45 and compares with the $11.41 52-week low. The stock recovered 335.5% since its low point and has performed 304.97% year-to-date.